C12N 2760/20071
Demonstrated in vivo effect
C12N2760/20071 (Demonstrated in vivo effect) appears on 4 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 9
- Assignees
- 5
- Inventors
- 12
- Latest grant
- 28 May 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 2 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
By publication year.
Recent patents
- Rabies virus vaccine28 May 2024US 11,992,526 B2Intervet Inc.
- Oncolytic rhabdovirus20 Feb 2018US 9,896,664 B2Turnstone Limited Partnership
- Formulations for non-invasive delivery of active proteins to an animal or human8 Nov 2016US 9,486,516 B2Bioorganic Research and Services SA
- Oncolytic rhabdovirus2 Jun 2015US 9,045,729 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof4 Jan 2024US 2024/0000920 A1Intervet Inc.
- Heterologous combination prime:boost therapy and methods of treatment6 Jul 2023US 2023/0210970 A1Children's Hospital of Eastern Ontario Research Institute Inc.
- Heterologous combination prime:boost therapy and methods of treatment25 Feb 2021US 2021/0052712 A1Children's Hospital of Eastern Ontario Research Institute Inc.
- Rabies virus vaccine5 Nov 2020US 2020/0345832 A1Intervet Inc.
- Oncolytic virus and checkpoint inhibitor combination therapy7 Mar 2019US 2019/0070280 A1Turnstone Limited Partnership
Most cited
By later US patents